However, whereas in previous studies EGFR pathway inhibition led to upregulation of the c-Met pathway or both pathways existed in parallel, we demonstrate that in c-Met+ HCC models, c-Met pathway inhibition leads to EGFR pathway upregulation. The gene discussed is MET; the disease is hepatocellular carcinoma.